Table 2.
Characteristics and clinical outcome of kidney transplantation.
| PTx group (n = 49) |
Cinacalcet group (n = 98) | No treatment group (n = 133) | Total (n = 280) |
P-value | |
|---|---|---|---|---|---|
| Donor type | .638 | ||||
| Deceased | 111 (83.5%) | 86 (87.8%) | 111 (83.5%) | 238 (85.0%) | |
| Living | 22 (16.5%) | 12 (12.2%) | 22 (16.5%) | 42 (15.0%) | |
| Donor age | 34 ± 12 | 36 ± 16 | 39 ± 13 | 37 ± 14 | .123 |
| KDPI (%), median (IQR) | 30.0 (20.0-62.0) |
37.5 (23.0-67.5) |
55.0 (33.5-70.5) |
51.0 (23.0-68.0) |
.080 |
| % PRA I, median (IQR) | 0 (0-3) | 0 (0-10) | 0 (0-23.3) | 0 (0-14) | .745 |
| % PRA II, median (IQR) | 0 (0-3) | 0 (0-3) | 0 (0-3) | 0 (0-3) | .750 |
| Shared antigen (n/10) | 3.0 ± 2.0 | 2.2 ± 1.6 | 3.0 ± 2.0 | 2.7 ± 1.9 | .013 |
| Anastomosis | .782 | ||||
| UC | 43 (87.8%) | 87 (88.8%) | 114 (85.7%) | 244 (87.1%) | |
| UU | 6 (12.2%) | 11 (11.2%) | 19 (14.3%) | 36 (12.9%) | |
| Induction immunosuppression | .074 | ||||
| Thymoglobulin | 36 (73.5%) | 70 (71.4%) | 95 (71.4%) | 201 (71.8&) | |
| Basiliximab | 1 (2.0%) | 7 (7.1%) | 19 (14.3%) | 27 (9.6%) | |
| Alemtuzumab | 11 (22.4%) | 21 (21.4%) | 17 (12.8%) | 49 (17.5%) | |
| Thymoglobulin and Basiliximab | 1 (2.0%) | 0 | 2 (1.5%) | 3 (1.1%) | |
| Maintenance immunosuppression | |||||
| Tacrolimus | 49 (100%) | 98 (100%) | 133 (100%) | — | |
| Mycophenolate | 48 (98.0%) | 98 (100%) | 131 (98.5%) | 277 (98.9%) | .326 |
| Prednisone | 40 (81.6%) | 78 (79.6%) | 116 (87.2%) | 234 (83.6%) | .276 |
| DGF | 3 (6.1%) | 13 (13.3%) | 22 (16.5%) | 38 (13.6%) | .190 |
| Rejection before discharge | 0 | 0 | 1 (0.8%) | 1 (0.4%) | .574 |
| Rejection 6 months post-KT | 0 | 0 | 1 (0.8%) | 1 (0.4%) | .165 |
| Rejection 1 yr post-RTx | 0 | 0 | 1 (0.8%) | 1 (0.4%) | .868 |
| Death (%) | 4 (8.2%) | 15 (15.3%) | 38 (28.6%) | 57 (20.4%) | .003 |
| Death-censored graft failure (%) | 2 (4.1%) | 3 (3.1%) | 22 (16.5%) | 27 (9.6%) | <.001 |
| All-cause graft failure (%) | 6 (12.2%) | 18 (18.4%) | 53 (39.8%) | 77 (27.5%) | <.001 |
| PTH on admission for KT, pg/mL, median (IQR) |
718 (324-953) |
511 (311-944) |
401 (257-644) |
472 (282-773) |
.002 |
| Serum calcium on admission for KT, mg/dL (mean ± SD) | 9.7 ± 0.9 | 9.3 ± 0.9 | 9.4 ± 0.9 | 9.4 ± 0.9 | .077 |
| Hypercalcemia on admission for KT | 10 (20.4%) | 9 (9.2%) | 10 (7.5%) | 29 (10.4%) | .036 |
| Cinacalcet use on admission for KT | 39 (79.6%) | 70 (71.4%) | 64 (48.1%) | 173 (61.8%) | <.001 |
| Time from KT to first hypercalcemia, months Median (IQR) |
0 (0-1) | 0 (0-2) | 2.0 (0-6) | 1 (0-4) | <.001 |
| Most recent PTH pg/mL, median (IQR) |
147 (80-273) |
207 (148-310) |
169 (124-306) |
183 (126-306) |
.012 |
| Most recent serum calcium mg/dL, (mean ± SD) | 9.1 ± 0.8 | 9.8 ± 0.7 | 9.7 ± 0.8 | 9.6 ± 0.8 | <.001 |
Abbreviations: DGF = delayed graft function; KDPI = Kidney Donor Profile Index; %PRA = percent panel reactive antibody; UC = Ureterovesical anastomosis, UU = Ureteroureterostomy.